A subset of patients with hematologic malignancies develop immune-based refractoriness to platelet transfusions. Diagnosing and dealing with platelet refractoriness is critical for a patient’s survival. This program will explore the basis of refractoriness, standard strategies used, and alternative

This program will introduce the 12th Edition of AABB Standards for Cellular Therapy Services. The speakers will summarize the new and revised requirements incorporated into the 12th Edition of Standards. In addition, the rationale for the changes will be presented and reviewed. Presented by

Clinically insignificant high incidence antibodies, also known as high titer low avidity (HTLA) reacting antibodies, can be confusing and cause difficulty in antibody identification. This program will provide a lecture-based overview of the blood group antigens associated with these antibodies and

For many patients with sickle cell disease (SCD), hematopoietic stem cell transplantation is unavailable due to lack of a matched donor. Gene therapy using autologous gene-edited stem cells has emerged as an option for these patients. Two gene therapy regimens have been approved by the FDA and

Clinical medicine is rife with ethical issues. Even though the laboratory is largely removed from direct patient-facing care, ethical issues commonly arise. Having a framework for identifying, analyzing, and resolving ethical dilemmas is key to ensuring excellent patient care and a safe environment

Cellular therapy products are cryopreserved and stored in liquid nitrogen freezers for subsequent transplantation into recipients. Storage duration is variable but is typically a few weeks to a few years. Unused products may continue to be stored for many decades after the recipient has been

The Association for the Advancement of Blood & Biotherapies (AABB) 2025 Annual Meeting will be hosted in San Diego, California on October 25–28, 2025. The AABB Annual Meeting brings blood and biotherapies professionals together to share cutting-edge research, unique perspectives, networking with

This lecture is part of the CBR lecture series. Held on Wednesdays from 1-2pm PT, CBR seminars feature insightful scientific talks, with speakers from a range of clinical, industry and academic backgrounds. Presented by Dr. Samira Mubareka University of Toronto Hosted by Dr. Chris Overall

Myeloid malignancies are uncommon but deadly cancers. Despite extensive investigation of coding mutations and the development of targeted therapies, there remains a major need for new therapies and treatment approaches. Decision-making around post-remission therapy is based on genetic risk

Respiratory Syncytial Virus (RSV) is the leading cause of infant hospitalizations worldwide. While there are vaccines for RSV in the elderly there are no vaccines or therapeutics for prevention and treatment of RSV in infants. To address these unmet needs we are studying the structure of viral